Skip to main
ESPR
ESPR logo

Esperion Therapeutics (ESPR) Stock Forecast & Price Target

Esperion Therapeutics (ESPR) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 19%
Hold 52%
Sell 5%
Strong Sell 0%

Bulls say

Esperion Therapeutics Inc. has reported substantial progress in its financial performance, highlighted by a 53% year-over-year increase in product revenue to $31.1 million for the most recent quarter, driven by notable retail prescription growth. The company's strategic partnership with Daiichi Sankyo Europe has resulted in a significant 19% sequential increase in royalty revenues, reflecting strong prescription growth for its products NILEMDO and NUSTENDI. Furthermore, improved commercial and Medicare coverage rates above 92% and 65%, respectively, indicate growing confidence from healthcare providers, promising an optimistic sales outlook for the company's therapeutic offerings in the coming quarters.

Bears say

Esperion Therapeutics Inc. faces a negative outlook primarily due to its historical pattern of financial losses and the lack of established profitability, which raises concerns about its long-term viability. Additionally, the company has been forced to incrementally lower its sales estimates, indicating potential challenges in meeting market expectations and sustaining revenue growth. Furthermore, the risk of competing breakthrough therapies could threaten the relevance of Esperion’s existing products, adding to the uncertainties surrounding its financial future and maintaining balance sheet stability.

Esperion Therapeutics (ESPR) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 19% recommend Buy, 52% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Esperion Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Esperion Therapeutics (ESPR) Forecast

Analysts have given Esperion Therapeutics (ESPR) a Buy based on their latest research and market trends.

According to 21 analysts, Esperion Therapeutics (ESPR) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Esperion Therapeutics (ESPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.